FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593352313> ?p ?o ?g. }

• W2593352313 endingPage "13" @default.
• W2593352313 startingPage "PD6" @default.
• W2593352313 abstract "Abstract Background: Eribulin mesylate (ERI), a nontaxane microtubule inhibitor with effects on tumor biology (increased vascular perfusion, reversal of epithelial to mesenchymal transition), is approved as a monotherapy for the treatment of patients (pts) with metastatic breast cancer who received ≥2 prior chemotherapeutic regimens for metastatic disease. In a pooled analysis, ERI significantly prolonged OS compared with capecitabine or treatment of physician's choice in pts with metastatic triple-negative breast cancer (mTNBC; 12.9 vs 8.2 mo, n=428). Pembrolizumab (PEM) is a human programmed death (PD) receptor-1–blocking antibody approved for the treatment of several advanced cancers. In a phase (Ph) 2 study in mTNBC, PEM monotherapy as first-line therapy demonstrated ORR, 23%; median PFS, 2.1 mo [95% CI 2.0-3.9], and in pts pretreated with ≥1 prior chemotherapy demonstrated ORR, 5%; median OS, 8.9 mo [95% CI 7.2-11.2]). Methods:This open-label Ph 1b/2 trial enrolled pts (aged ≥18 yrs; ECOG PS ≤1) with mTNBC treated with ≤2 prior lines of chemotherapy for metastatic disease. Ph 1b included a safety cohort of ≥6 pts who received intravenous (IV) ERI 1.4 mg/m2 on day (d) 1 and d8 and IV PEM 200 mg on d1 of a 21-d cycle. In Ph 2, pts were enrolled based on prior chemotherapy in the metastatic setting [0 vs 1–2 lines]. Primary endpoints: safety, tolerability (Ph 1b), and ORR (Ph 2); secondary endpoints: PFS, OS, and efficacy in PD-L1+ pts. Results: We report data from 82 of 104 enrolled pts (data cut-off Nov 1, 2016).The RP2D was ERI 1.4 mg/m2 on d1 and d8 and PEM 200 mg on d1 of a 21-d cycle. Most common treatment-emergent adverse events (TEAEs) were fatigue (73.2%), nausea (51.2%), peripheral sensory neuropathy (46.3%), alopecia (43.9%), and pyrexia (36.6%). Most common Grade (G) 3 or 4 TEAEs related to ERI: neutropenia (29.3%), peripheral neuropathy (8.5%), and asthenia/fatigue (7.3%). G3/4 immune-related TEAEs related to PEM: 19.5% of pts. TEAEs that led to drug withdrawal/dose reduction: 18.3%/28.0% of pts. G5 events: 3 pts (respiratory failure, pleural effusion, and multiple organ failure; none related to study drug). Response was irrespective of PD-L1 status (Table1). Results of the final analysis will be available for presentation. Overall (n=82)No prior chemotherapy in metastatic setting (n=48)1-2 Prior lines of chemotherapy in metastatic setting (n=34)PD-L1+ (n=35)PD-L1- (n=36)ORR, n (%) [95% CIa]21 (25.6) [16.8, 35.4]12 (25.0) [14.0, 37.8]9 (26.5) [13.3, 41.8]9 (25.7) [12.9, 40.8]9 (25.0) [12.5, 39.8]CBRb, n (%)25 (30.5)13 (27.1)12 (35.3)10 (28.6)12 (33.3)DCRc, n (%)46 (56.1)28 (58.3)18 (52.9)19 (54.3)21 (58.3)Median PFS, mo [95% CI]4.1 [2.3-4.8]4.1 [2.2-4.9]3.9 [2.1-6.3]4.1 [2.1-4.8]4.1 [2.3-6.3]Median OS, mo [95% CI]NE [17.7-NE]17.7 [13.7-NE]NE [13.1-NE]----a Credible interval from Bayesian analysis; b clinical benefit rate = CR+PR+SD; c disease control rate = CR+PR+SD ≥24 weeks. NE, not estimable. Conclusions: ERI+PEM was well tolerated and demonstrated activity in pts with mTNBC. The combination resulted in improved ORR, with longer PFS, OS, and comparable TEAEs to those observed with either treatment as monotherapy. Further exploration of this combination is warranted. Citation Format: Tolaney SM, Kalinsky K, Kaklamani V, Savulsky C, Olivo M, Aktan G, Kaufman PA, Xing D, Almonte A, Misir S, Karantza V, Diab S. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD6-13." @default.
• W2593352313 created "2017-03-16" @default.
• W2593352313 creator A5003097936 @default.
• W2593352313 creator A5003681784 @default.
• W2593352313 creator A5024967501 @default.
• W2593352313 creator A5029843687 @default.
• W2593352313 creator A5032459330 @default.
• W2593352313 creator A5033494478 @default.
• W2593352313 creator A5046835606 @default.
• W2593352313 creator A5047788825 @default.
• W2593352313 creator A5047918797 @default.
• W2593352313 creator A5055781858 @default.
• W2593352313 creator A5058784740 @default.
• W2593352313 creator A5077520870 @default.
• W2593352313 date "2018-02-15" @default.
• W2593352313 modified "2023-10-16" @default.
• W2593352313 title "Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer" @default.
• W2593352313 doi "https://doi.org/10.1158/1538-7445.sabcs17-pd6-13" @default.
• W2593352313 hasPublicationYear "2018" @default.
• W2593352313 type Work @default.
• W2593352313 sameAs 2593352313 @default.
• W2593352313 citedByCount "37" @default.
• W2593352313 countsByYear W25933523132018 @default.
• W2593352313 countsByYear W25933523132019 @default.
• W2593352313 countsByYear W25933523132020 @default.
• W2593352313 countsByYear W25933523132021 @default.
• W2593352313 countsByYear W25933523132022 @default.
• W2593352313 countsByYear W25933523132023 @default.
• W2593352313 crossrefType "journal-article" @default.
• W2593352313 hasAuthorship W2593352313A5003097936 @default.
• W2593352313 hasAuthorship W2593352313A5003681784 @default.
• W2593352313 hasAuthorship W2593352313A5024967501 @default.
• W2593352313 hasAuthorship W2593352313A5029843687 @default.
• W2593352313 hasAuthorship W2593352313A5032459330 @default.
• W2593352313 hasAuthorship W2593352313A5033494478 @default.
• W2593352313 hasAuthorship W2593352313A5046835606 @default.
• W2593352313 hasAuthorship W2593352313A5047788825 @default.
• W2593352313 hasAuthorship W2593352313A5047918797 @default.
• W2593352313 hasAuthorship W2593352313A5055781858 @default.
• W2593352313 hasAuthorship W2593352313A5058784740 @default.
• W2593352313 hasAuthorship W2593352313A5077520870 @default.
• W2593352313 hasConcept C121608353 @default.
• W2593352313 hasConcept C126322002 @default.
• W2593352313 hasConcept C143998085 @default.
• W2593352313 hasConcept C197934379 @default.
• W2593352313 hasConcept C203092338 @default.
• W2593352313 hasConcept C2775930923 @default.
• W2593352313 hasConcept C2776387010 @default.
• W2593352313 hasConcept C2776694085 @default.
• W2593352313 hasConcept C2777701055 @default.
• W2593352313 hasConcept C2777909004 @default.
• W2593352313 hasConcept C2778375690 @default.
• W2593352313 hasConcept C2780057760 @default.
• W2593352313 hasConcept C2780110267 @default.
• W2593352313 hasConcept C31760486 @default.
• W2593352313 hasConcept C526805850 @default.
• W2593352313 hasConcept C530470458 @default.
• W2593352313 hasConcept C535046627 @default.
• W2593352313 hasConcept C71924100 @default.
• W2593352313 hasConcept C90924648 @default.
• W2593352313 hasConceptScore W2593352313C121608353 @default.
• W2593352313 hasConceptScore W2593352313C126322002 @default.
• W2593352313 hasConceptScore W2593352313C143998085 @default.
• W2593352313 hasConceptScore W2593352313C197934379 @default.
• W2593352313 hasConceptScore W2593352313C203092338 @default.
• W2593352313 hasConceptScore W2593352313C2775930923 @default.
• W2593352313 hasConceptScore W2593352313C2776387010 @default.
• W2593352313 hasConceptScore W2593352313C2776694085 @default.
• W2593352313 hasConceptScore W2593352313C2777701055 @default.
• W2593352313 hasConceptScore W2593352313C2777909004 @default.
• W2593352313 hasConceptScore W2593352313C2778375690 @default.
• W2593352313 hasConceptScore W2593352313C2780057760 @default.
• W2593352313 hasConceptScore W2593352313C2780110267 @default.
• W2593352313 hasConceptScore W2593352313C31760486 @default.
• W2593352313 hasConceptScore W2593352313C526805850 @default.
• W2593352313 hasConceptScore W2593352313C530470458 @default.
• W2593352313 hasConceptScore W2593352313C535046627 @default.
• W2593352313 hasConceptScore W2593352313C71924100 @default.
• W2593352313 hasConceptScore W2593352313C90924648 @default.
• W2593352313 hasIssue "4_Supplement" @default.
• W2593352313 hasLocation W25933523131 @default.
• W2593352313 hasOpenAccess W2593352313 @default.
• W2593352313 hasPrimaryLocation W25933523131 @default.
• W2593352313 hasRelatedWork W2087736549 @default.
• W2593352313 hasRelatedWork W2196426442 @default.
• W2593352313 hasRelatedWork W2382613782 @default.
• W2593352313 hasRelatedWork W2530268457 @default.
• W2593352313 hasRelatedWork W2796100748 @default.
• W2593352313 hasRelatedWork W2978552006 @default.
• W2593352313 hasRelatedWork W3031563781 @default.
• W2593352313 hasRelatedWork W4205779066 @default.
• W2593352313 hasRelatedWork W4254679361 @default.
• W2593352313 hasRelatedWork W3129921008 @default.
• W2593352313 hasVolume "78" @default.
• W2593352313 isParatext "false" @default.
• W2593352313 isRetracted "false" @default.
• W2593352313 magId "2593352313" @default.
• W2593352313 workType "article" @default.